Tag: axial spondyloarthritis
Positive results for Taltz in COAST-X trial
Results from the COAST-X trial show that patients treated with Taltz (ixekizumab, Eli Lilly and Company) achieved improvement in the signs and symptoms of...
Novartis announces results of PREVENT study
Novartis today announced detailed results from the randomised, double-blind, placebo-controlled phase III PREVENT study, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients...
CIMZIA effective in treating axial spondyloarthritis patients
CIMZIA (certolizumab pegol) is the first therapy to demonstrate positive results in a 52-week, placebo controlled non-radiographic axial spondyloarthritis study. The positive topline results...